American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch
Daiichi Sankyo Affiliate Holds 505(b)(2) NDA Approval For Vasostrict Rival
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.
